Literature DB >> 28114798

Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial.

Masoume Malekolkottab1, Hossein Khalili1, Mostafa Mohammadi2, Masoud Ramezani2, Anahid Nourian1.   

Abstract

AIM: Metoclopramide is commonly used as a prokinetic agent in critically ill patients with enteral feeding intolerance. In this study, noninferiority of metoclopramide as intermittent versus continuous infusion was examined in critically ill patients with enteral feeding intolerance.
METHODS: Forty critically ill adults patients were assigned to receive metoclopramide as either intermittent (10 mg every 6 h) or continuous (2 mg/h) infusion. Frequency of feeding intolerance and adverse effects of metoclopramide were assessed during 7 days of study.
RESULTS: Number of patients with feeding intolerance during different times of the course was not different between the groups. Although not statistically significant, diarrhea and cardiac rhythm were more common in continuous than intermittent infusion group.
CONCLUSION: Continuous and intermittent infusions of metoclopramide showed equivalent effectiveness in critically ill patients.

Entities:  

Keywords:  continuous infusion; intermittent infusion; metoclopramide

Mesh:

Substances:

Year:  2017        PMID: 28114798     DOI: 10.2217/cer-2016-0067

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

1.  The efficacy and safety of prokinetics in critically ill adults receiving gastric feeding tubes: A systematic review and meta-analysis.

Authors:  Rong Peng; Hailong Li; Lijun Yang; Linan Zeng; Qiusha Yi; Peipei Xu; Xiangcheng Pan; Lingli Zhang
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

2.  Comparison of continuous versus intermittent enteral nutrition in critically ill patients (COINN): study protocol for a randomized comparative effectiveness trial.

Authors:  Ondrej Hrdy; Kamil Vrbica; Eva Strazevska; Petr Suk; Lenka Souckova; Radka Stepanova; Igor Sas; Roman Gal
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.